- Home
- NCPL vs XBIO Comparison
NCPL vs XBIO Comparison
Compare NCPL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- XBIO
- Stock Information
- Founded
- NCPL 1984
- XBIO N/A
- Country
- NCPL United States
- XBIO United States
- Employees
- NCPL N/A
- XBIO N/A
- Industry
- NCPL Investment Managers
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- XBIO Health Care
- Exchange
- NCPL Nasdaq
- XBIO Nasdaq
- Market Cap
- NCPL 4.3M
- XBIO 4.2M
- IPO Year
- NCPL N/A
- XBIO N/A
- Fundamental
- Price
- NCPL $1.92
- XBIO $3.06
- Analyst Decision
- NCPL
- XBIO Hold
- Analyst Count
- NCPL 0
- XBIO 1
- Target Price
- NCPL N/A
- XBIO N/A
- AVG Volume (30 Days)
- NCPL 42.6K
- XBIO 11.2K
- Earning Date
- NCPL 03-17-2025
- XBIO 05-20-2025
- Dividend Yield
- NCPL N/A
- XBIO N/A
- EPS Growth
- NCPL N/A
- XBIO N/A
- EPS
- NCPL N/A
- XBIO N/A
- Revenue
- NCPL $812,612.00
- XBIO $2,500,284.00
- Revenue This Year
- NCPL N/A
- XBIO $14.23
- Revenue Next Year
- NCPL $101.16
- XBIO N/A
- P/E Ratio
- NCPL N/A
- XBIO N/A
- Revenue Growth
- NCPL N/A
- XBIO N/A
- 52 Week Low
- NCPL $1.41
- XBIO $2.20
- 52 Week High
- NCPL $22.82
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- NCPL 50.02
- XBIO 58.94
- Support Level
- NCPL $1.75
- XBIO $2.78
- Resistance Level
- NCPL $2.15
- XBIO $3.39
- Average True Range (ATR)
- NCPL 0.10
- XBIO 0.22
- MACD
- NCPL -0.01
- XBIO 0.09
- Stochastic Oscillator
- NCPL 42.50
- XBIO 69.19
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.